Snap Shot Audit Early Onset Colorectal Cancer - Are we doing enough or can we do more?

• Conditions: C18; C19; C20; Malignant neoplasm of colon; Malignant neoplasm of rectosigmoid junction; Malignant neoplasm of rectum

• Registration Number: DRKS00031228
• Lead Sponsor: Clarunis – Universitäres Bauchzentrum Basel

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-04-19
• Study Completion: 2024-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 650

Inclusion Criteria

new diagnosed colorectal carcinoma which qualifies for oncological therapy (palliative therapies included)
- Patients who have consented to the further use of their clinical data for research (general consent granted)

Exclusion Criteria

- the colorectal carcinoma has not been confirmed
- the colorectal carcinoma was not defined as a primary carcinoma (e.g. colorectal metastasis of another underlying tumor disease)
- Missing general consent

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Modality of Diagnosis, Time to Diagnosis

Secondary Outcome Measures

Name	Time	Method
- Evaluation of surgical techniques (open vs. minimal-invasive, CME, TME, extend of lymph node resection) in younger patients with colorectal cancer<br>-Evaluation of systemic therapies (neoadjuvant/adjuvant Chemotherapy, Radiation, total neoadjuvant therapy or immune therapy) in younger patients with colorectal carcinomas